Cargando…
Metabolic and Vascular Imaging Biomarkers in Down Syndrome Provide Unique Insights Into Brain Aging and Alzheimer Disease Pathogenesis
People with Down syndrome (DS) are at high risk for developing Alzheimer disease (AD). Neuropathology consistent with AD is present by 40 years of age and dementia may develop up to a decade later. In this review, we describe metabolic and vascular neuroimaging studies in DS that suggest these funct...
Autores principales: | Head, Elizabeth, Powell, David K., Schmitt, Frederick A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021507/ https://www.ncbi.nlm.nih.gov/pubmed/29977201 http://dx.doi.org/10.3389/fnagi.2018.00191 |
Ejemplares similares
-
Exploring the role of sex differences in Alzheimer's disease pathogenesis in Down syndrome
por: Andrews, Elizabeth J., et al.
Publicado: (2022) -
Con: are we ready to translate Alzheimer’s disease-modifying therapies to people with down syndrome?
por: Head, Elizabeth, et al.
Publicado: (2014) -
Neuroimaging Biomarkers of mTOR Inhibition on Vascular and Metabolic Functions in Aging Brain and Alzheimer’s Disease
por: Lee, Jennifer, et al.
Publicado: (2018) -
Cerebrovascular pathology in Down syndrome and Alzheimer disease
por: Head, Elizabeth, et al.
Publicado: (2017) -
The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer’s disease biomarkers in down syndrome
por: Rafii, Michael S., et al.
Publicado: (2015)